De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial
2021; AlphaMed Press; Volume: 26; Issue: 6 Linguagem: Inglês
10.1002/onco.13742
ISSN1549-490X
AutoresBrett A. Miles, Marshall R. Posner, Vishal Gupta, Marita S. Teng, Richard L. Bakst, Mike Yao, K. Misiukiewicz, Raymond L. Chai, Sonam Sharma, William H. Westra, Seunghee Kim‐Schulze, Bheesham D. Dayal, Stanisław Sobótka, Andrew G. Sikora, Peter M. Som, Eric M. Genden,
Tópico(s)Salivary Gland Tumors Diagnosis and Treatment
ResumoTreatment of human papillomavirus-related oropharyngeal squamous cell carcinoma (HPVOPC) results in unprecedented high survival rates but possibly unnecessary toxicity. We hypothesized that upfront surgery and neck dissection followed by reduced-dose adjuvant therapy for early and intermediate HPVOPC would ultimately result in equivalent progression-free survival (PFS) and overall survival while reducing toxicity.
Referência(s)